Experience of therapy of psoriasis patients with methotrexate in the form of subcutaneous and intramuscularly injections

Psoriasis is one of the most common chronic dermatoses. About 125 million patients with this disease are registered in the world, and the frequency of occurrence in the structure of dermatological diseases is about 40%. Despite the fact that in most cases psoriasis does not pose a threat to life, but, nevertheless, it is the direct cause of the appearance of very serious pathological problems, social maladjustment. Recently, an increasing number of researchers speak of psoriasis not as an isolated skin disease, but as a systemic 8psoriatic disease9 with dominant skin manifestations. The 8systemic nature9 of the disease is manifested in the frequent involvement in the process of not only the skin, but also other systems and organs, in particular, the musculoskeletal system in the arthropathic form of psoriasis (psoriatic arthritis). The prevalence of psoriatic arthritis in patients with psoriasis ranges from 7 to 47%, and in 15% of patients arthritis develops before skin lesions, with ordinary psoriasis, arthritis occurs in 6-7% of cases, and with already identified psoriatic arthropathy in 73,2%, pustular or exudative psoriasis, as well as psoriatic erythroderma. The article presents the results of the use of methotrexate in the form of subcutaneous injections in clinical practice in the treatment of patients with moderate and severe psoriasis, in comparison with a similar scheme of using intramuscular injections of methotrexate. The course of methotrexate therapy has been shown to be highly effective in the treatment of psoriasis and psoriatic arthritis. The data on higher safety, a more significant positive effect on the quality of life, better toler ability and longer remission of the process achieved in a group of patients receiving subcutaneous injections of methotrexate are presented.

1. Global report on psoriasis. World Health Organization. 2016. Доступно: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf.

2. Potekayev N. N., Kruglova L. S. Psoriatic disease. Moskva. MDV, 2014. P. 264.

3. Olisova O. Yu., Garanyan L. G. Epidemiology, etiopathogenesis and comorbidity of psoriasis – new facts // Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney. 2017; 20 (4): 214-219.

4. Bakulev A. L. Psoriasis: clinical features, risk factors and associated comorbid conditions. Klin. farmakol. ter. 2019; 28 (1): 35-39.

5. Shapovalov R. G., Silina L. V., Bobyntsev I. I., Pis'mennaya Ye. V. Study of quality of life indicators in patients with widespread psoriasis using the SP-36 questionnaire // Vestnik novykh meditsinskikh tekhnologiy. 2011; 18 (1): 90-92.

6. Bunchuk N. V., Badokin V. V., Korotayeva T. V. Psoriatic arthritis // V kn. Revmatologiya natsional'noye rukovodstvo / Pod red. Ye. L. Nasonova, V. A. Nasonovoy. M.: GEOTAR-MEDIA, 2008. P. 355-366.

7. Burdeynyy A. P. Psoriatic arthritis // V kn. Revmaticheskiye bolezni / Pod red. V. A. Nasonovoy, N. V. Bunchuk. M.: Meditsina, 1997. S. 314-324.

8. Schnabel A., Gross W. L. Low-dose methotrexate in rheumatic diseases – Efficacy, side effects, and risk factors for side effects // Semin. Arthritis Rheum. 1994; 23: 310-327. DOI: 10.1016/0049-0172(94)90027-2.

9. Rudwaleit M., Yin Z., Siegert S., Grolms M., Radbruch A. et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor α, increase of interleukin 10, and predicted by the initial concentration of interleukin 4 // Ann. Rheum. Dis. 2000; 59: 311-314.

10. Bedoui Y., Guillot X., Sélambarom J., Guiraud P., Giry C., et al. Methotrexate an Old Drug with New Tricks // Int J Mol Sci. 2019; 20 (20): 5023.

11. Nasonov E. L. Methotrexate in rheumatoid arthritis – 2015: new facts and ideas // Nauchnoprakticheskaya revmatologiya. 2015; 53 (5s): 64-76.

12. Gallyamova Yu. A., Asoskova A. V. Methotrexate in dermatology: from theory to practice. The Lechaschi Vrach Journal. 2021; 5 (24): 46-51.

13. Saurat J. H., Langley R. G., Reich K. et al. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study // Br J Dermatol. 2011; 165 (2): 399-406.

14. Matushevskaya E. V., Svirshchevskaya Ye. V., Matushevskaya Yu. I. Issues of safety and effectiveness of systemic therapy for psoriasis // Klinicheskaya dermatologiya i venerologiya. 2014; 2: 4-9.

15. Carrascosa J. M., de la Cueva P., Ara M. et al. Methotrexate in moderate to severe psoriasis: review of the literature and expert recommendations // Actas Dermosifiliogr. 2016; 107 (3): 194-206.

16. Clinical guidelines. Psoriasis. 2020. Dostupno: https://cr.minzdrav.gov.ru/clin_recomend.

17. Romão V. C., Lima A., Bernardes M., Canhão H., Fonseca J. E. Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity? // Immunol. Res. 2014; 60: 289-310. DOI: 10.1007/s12026-014-8564-6.

18. Manalo I. F., Gilbert K., Wu J. J. Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability // Psoriasis: Targets and Therapy. 2015; 5: 65-69.

19. Owczarczyk-Saczonek A., Drozdowski M., Maciejewska-Radomska A., Choszcz D., Placek W. The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients – preliminary report // Dermatol Allergol 2018; 35 (1): 53-59. DOI: https://doi.org/10.5114/ada.2017.71358.